Please assess the completion status of the following clinical trial:

Trial Title: Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy men,~2. Age between 18 and 45 years~3. Normal weight (according to the table provided by Metropolitan Life Insurance).~Exclusion Criteria:~1. Hypersensitivity to opioids or naloxone,~2. History of addictive disease,~3. Significant cardiac, respiratory, gastrointestinal, neurological, dermatological, and psychiatric diseases,~4. Concurrent medication with an analgesic drug,~5. Student and employees affiliated with our laboratory

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Propranolol, Then Placebo (Type: ACTIVE_COMPARATOR): Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
- Placebo, Then Propranolol (Type: PLACEBO_COMPARATOR): Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).